@RadarContact13 @NPR This isn't a matter of immune fitness. Some tumors evolve to express a signal that prevents recognition and detruction by T-cells. The drug used in this trial blocks that signaling. https://t.co/2os6DYN7Os https://t.co/lKMbiQSV7b
534 followers
3,232 followers
RT @FrontCellDevBio: New Research: Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors: In cancer-immunity cycle, the immune che…
3,902 followers
New Research: Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors: In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as accomplices to help tumors resist to immunity-induced apoptosis and promote tumor… https://t.co/N0t